The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART
Latest Information Update: 27 Mar 2023
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms The DTG-SWITCH Study
- 23 Mar 2023 Status changed from active, no longer recruiting to completed.
- 14 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2020 New trial record